跳至主要内容
临床试验/NCT02505581
NCT02505581已完成4 期

Preoperative Oral Antibiotics and Surgical Site Infections in Colon Surgery Without Mechanical Bowel Preparation. A Prospective, Multicentre, Single Blinded, Randomized Trial (ORALEV Study)

Hospital Universitari Vall d'Hebron Research Institute3 个研究点 分布在 1 个国家目标入组 536 人开始时间: 2015年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
536
试验地点
3
主要终点
Wound infection

研究概览

简要总结

Routine antibiotics for the intravenous and oral prophylaxis of colorectal surgery will be used.

Experimental group: Patients undergoing elective colorectal surgery that involves, colonic resection.

The antibiotic prophylaxis in this group will be composed of:

An oral antibiotic pattern of ciprofloxacin (750mg / 12h, 2 doses) and metronidazole (250mg / 8h, 3 doses) the day before surgery.

Control group: Patients undergoing elective colorectal surgery that involves, colonic resection.

The antibiotic prophylaxis in this group will be composed of:

An intravenous antibiotic pattern of cefuroxime 1g and metronidazole 1,5gr during anesthetic induction.

In both groups a second intravenous dose of cefuroxime (750mg) will be administered if the intraoperative time elongates more than three hours or there is an intraoperative bleeding over 1000cc.

There won´t be a placebo treatment. Subject compliance will be evaluated according to the usual practice in surgical care field

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients presenting colonic pathology
  • The surgery is not contraindicated
  • Diagnosis of colorectal neoplasia or diverticular disease with surgical indication (stenosis, chronic constipation, recurrent infections etc ..)
  • Indication of segmentary resection or total colectomy
  • Patients who agree to participate voluntarily in the study and signed an informed consent.

排除标准

  • Patients who refuse to participate in the study.
  • Patients undergoing mechanical colon preparation the day before surgery.
  • Patients with rectal cancer
  • Patients with intra-abdominal sepsis before surgery (abscess, diverticulitis).
  • Patients who received preoperative antibiotics for any reason in the two weeks prior to surgery.
  • Patients with inflammatory bowel disease (ulcerative colitis, Crohn's disease and indeterminate colitis)
  • Patients presenting allergy to the drugs under study.
  • Patients that will not strictly follow the assigned prophylaxis regimen
  • Patients undergoing urgent surgery (<24h)

研究组 & 干预措施

Oral + Parenteral prophylaxis

Experimental

干预措施: Colorectal Surgery (Procedure)

Oral + Parenteral prophylaxis

Experimental

干预措施: Extra dosage - cefuroxime (750mg) I.V (Drug)

Oral + Parenteral prophylaxis

Experimental

干预措施: Ciprofloxacin 750 mg oral (Drug)

Oral + Parenteral prophylaxis

Experimental

干预措施: Metronidazole 250 mg oral (Drug)

Oral + Parenteral prophylaxis

Experimental

干预措施: Cefuroxime 1.5 g Intravenous (Drug)

Oral + Parenteral prophylaxis

Experimental

干预措施: Metronidazole 1 g Intravenous (Drug)

Only Parenteral prophylaxis

Active Comparator

干预措施: Extra dosage - cefuroxime (750mg) I.V (Drug)

Only Parenteral prophylaxis

Active Comparator

干预措施: Colorectal Surgery (Procedure)

Only Parenteral prophylaxis

Active Comparator

干预措施: Cefuroxime 1.5 g Intravenous (Drug)

Only Parenteral prophylaxis

Active Comparator

干预措施: Metronidazole 1 g Intravenous (Drug)

结局指标

主要结局

Wound infection

时间窗: 30 days

Superficial, deep, body-cavity This is a Clinical measure supported by image if necessary All the morbidity problems are reported independently

次要结局

  • Hospital stay(Participants will be followed for the duration of hospital stay, an expected average of 7 days)
  • Cardiac complications(30 days after surgery)
  • Nephro-urinary complications(30 days after surgery)
  • Respiratory complications(30 days after surgery)
  • Neurological complications(30 days after surgery)
  • Direct Adverse Drug Reactions(24 hours since the drug is taken)
  • Gastrointestinal complications(30 days after surgery)
  • Iatrogenic problems(30 days after surgery)
  • Bleeding problems(30 days after surgery)
  • Occlusive problems(30 days from surgery)
  • Impaired healing(30 days after surgery)
  • Vascular Complications(30 days after surgery)
  • Local infection(30 days after surgery)
  • Local complications(30 days after surgery)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验